GN之后序贯口服N治疗晚期乳腺癌的临床观察与分析  

Observation and analysis of gemcitabine combined vinorelbine × 8 regimen versus gemcitabine combined vinorelbine×4 follow oral N×4 regimen as chemotherapy for metastatic breast cancer

作　　者：张凯[1] 罗智辉[1] 黄湛[1] 宫绪萌 陈伟玲[1] ZHANG Kai;LUO Zhihui;HUANG Zhan;GONG Xumeng;CHEN Weiling(Department of Breast Oncology,Yuebei People’s Hospital,Shaoguan,Guangdong 512025,China)

机构地区：[1]汕头大学附属粤北人民医院乳腺外科,广东韶关512025

出　　处：《岭南现代临床外科》2018年第4期414-417,共4页Lingnan Modern Clinics in Surgery

摘　　要：目的比较GN(吉西他滨/长春瑞滨)4疗程后序贯GN×4(GN×8组)或序贯口服N×4方案(GN×4-N组)治疗对晚期乳腺癌(MBC)的疗效及不良反应。方法选取2014年1月至2015年12月确诊的晚期乳腺癌患者61人,采用GN×4疗程后序贯GN×4或序贯口服N×4方案化疗,比较患者的总有效率(ORR)及1年生存率。结果 GN×8组ORR为35.5%(11/31),其中CR 6.5%(2/31),PR 29%(9/31);GN×4-N组ORR为33.3%(10/30),其中CR 6.7%(2/30),PR 26.7%(8/30),两组ORR差异无统计学意义(P=0.925),GN×8组1年生存率为67.7%;GN×4-N组1年生存率为65.5%,两组1年生存率差异无统计学意义(P=0.576)。两组均无化疗相关死亡病例,主要不良反应为骨髓抑制及胃肠道反应。结论 GN4疗程后序贯GN×4或序贯口服N×4方案对于MBC均有较好的有效率,不良反应均可耐受。但从药物经济学及患者的生活质量上讲,GN×4-N更符合晚期治疗患者"低毒高效、服用方便"的原则。Objective To compare the efficacy and toxicities of gemcitabine combined(GN)×8 regimen and gemcitabine combined vinorelbine(GN)×4 follow oral N×4 regimen as chemotherapy for anthracycline-and taxane-resistant metastatic breast cancer(MBC).Methods Sixty-one patients were treated by GN or GN×4-N regimen.Overall response rate(ORR)and 1-year survival of two groups were assessed after treatment.Results CR was 6.5%(2/31)and PR was 29.0%(9/31)in GN group.2 patients(6.9%)had a complete response(CR)and 8 patients(27.6%)had a partial response(PR)in GN×4-N group.No statistically significant difference was observed in terms of ORR(35.5%vs.33.3%,P=0.925),or 1-year survival rate(67.7%vs.65.5%,P=0.576)of the two groups.No patients died in correlated with the two regimens.Myelosuppression and gastrointestinal tract reaction were the most common toxicities.Conclusion GN and GN×4-N regimens are both well effective for patients with anthracycline-and taxane-resistant MBC.Drug-related toxicities are tolerable.Two regimens can be considered as salvage regimens for those patients.

关 键 词：吉西他滨 口服长春瑞滨 乳腺癌 化疗 

分 类 号：R737.9[医药卫生—肿瘤]